BioPharma Dive39m
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
News Medical on MSN37m
Largest ALS patient-based iPSC repository opens new frontiers in research
In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest ...
John Driskell Hopkins on ALS research and coping with his diagnosis
Zac Brown Band's John Driskell Hopkins is turning his battle with ALS into a mission to help others: "When you're given a ...
News Medical on MSN17h
UCL scientists receive £78 million funding boost to develop treatment for motor neurone disease
A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 ...
FierceBiotech3d
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
Neurizon Therapeutics Announces Promising ALS Drug Results
Pharmaust Limited (AU:NUZ) has released an update. Neurizon Therapeutics has announced promising preclinical results for its lead drug ...
Neurizon Therapeutics Explores Promising ALS Treatment
Pharmaust Limited (AU:NUZ) has released an update. Neurizon Therapeutics Limited has reported promising preclinical results for its lead drug ...
Business Wire3d
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...